Phase 2b Controlled Trial of M72/AS01EVaccine to Prevent Tuberculosis

Author:

Van Der Meeren Olivier1ORCID,Hatherill Mark1,Nduba Videlis1,Wilkinson Robert J.1,Muyoyeta Monde1,Van Brakel Elana1,Ayles Helen M.1,Henostroza German1,Thienemann Friedrich1,Scriba Thomas J.1,Diacon Andreas1,Blatner Gretta L.1,Demoitié Marie-Ange1,Tameris Michele1,Malahleha Mookho1,Innes James C.1,Hellström Elizabeth1,Martinson Neil1,Singh Tina1,Akite Elaine J.1,Khatoon Azam Aisha1,Bollaerts Anne1,Ginsberg Ann M.1,Evans Thomas G.1,Gillard Paul1,Tait Dereck R.1

Affiliation:

1. From GlaxoSmithKline, Wavre, Belgium (O.V.D.M., M.-A.D., T.S., E.J.A., A.K.A., A.B., P.G.); South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology (M.H., T.J.S., M.T.), and Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (R.J.W., F.T.), University of Cape Town, Task Applied Science (E.V.B., A.D.), Stellenbosch University (A.D.), and Aeras...

Funder

Aeras Global Tuberculosis Vaccine Foundation

GlaxoSmithKline Biologicals SA

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3